

### **Remarks**

Claims 20 and 67-102 are allowed in this application. By this amendment, new claims 103-114 are added. The new claims, dependent from allowed composition claims 20, 67, 68, and 80, are added in order to include dependent claims directed to (i) effector molecules (claims 103-110) and (ii) a method of detecting a TAG-72-expressing tumor in a subject (claims 111-114); equivalent claims already depend from allowed composition claims 70 and 82. Support for new claims 103-110 can be found in the specification at least at page 26, lines 18-29. Support for new claims 111-114 can be found in the specification at least at page 31, line 26 through page 33, line 16.

As stated in the Examiner's Amendment, amendments to the claims may be filed under 37 CFR 1.312 after the mailing of the Notice of Allowance if the changes are submitted "no later than the payment of the issue fee." As this amendment is accompanied by the issue fee payment, Applicants submit that the addition of claims 103-114 is in accordance with 37 CFR 1.312. Applicants thank Examiner Blanchard for confirming with their representative, Dr. Anne Carlson, by both voicemail and email message on May 22, 2009, that it would be appropriate to submit the claims as amended herein with the payment of the issue fee.

Applicants respectfully request that the Examiner consider and enter this amendment, and that the Director approve this amendment, without withdrawing the application from issue. After entry of this amendment, **claims 20 and 67-114 will be pending**. As 51 claims have previously been paid for, Applicants believe that no additional claim fees are required.

### **Conclusion**

It is respectfully submitted that the present claims are in a condition for issuance. If it may further issuance of these claims, the Examiner is invited to call the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Anne Carlson/  
Anne Carlson, Ph.D.  
Registration No. 47,472